Biota partner to market
Monday, 30 March, 2009
Japanese biopharma Daiichi Sankyo, which co-owns a long-acting neuraminidase inhibitor for influenza with Australia’s Biota, has applied to manufacture and market the drug in Japan.
The contract depends on the successful completion of Phase III trials in Asia and on obtaining regulatory approval.
The trials have completed patient enrolment with results expected mid-year, Biota said in a statement.
The drug, CS-8958, is a long-acting flu drug which needs less frequent dosing than current neuraminidase inhibitors such as Roche’s oseltamivir (Tamiflu) and Biota’s own zanamivir (Relenza), which is marketed by GSK.
Daiichi Sankyo has rights to the drug in Japan, but Biota said all other key markets are available for licensing by the partners.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
